Global oncology informatics market will reach $8,602.3 million by 2030, growing by 6.1% annually over 2020-2030 driven by the surge of cancer incidence, increasing cost of cancer treatment, and growing trend of reducing medical errors and readmission rates.
Highlighted with 87 tables and 79 figures, this 170-page report “Global Oncology Informatics Market 2020-2030 by Product Type (EHR, PHM, CDSS, DDDI), Cancer Type, Application (Medical, Surgical, Radiation), End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global oncology informatics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global oncology informatics market in every aspect of the classification from perspectives of Product Type, Cancer Type, Application, End User, and Region.
Based on Product Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Electronic Health Records (EHRs)
- Population Health Management (PHM)
- Clinical Decision Support System (CDSS)
- Drug Discovery and Development Informatics (DDDI)
- Data Analytics
- Image Analytics
- Other Product Types
Based on Cancer Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Cervical Cancer
- Other Cancers
Based on Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Medical Application
- Surgical Application
- Radiation Application
Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Pharmaceutical Companies
- Life Science Companies
- Contract Research Organizations (CROs)
- Academic Institutes and Research Centers
- Other End Users
Geographically, the following regions together with the listed national/local markets are fully investigated:
- APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
- Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
- North America (U.S., Canada, and Mexico)
- South America (Brazil, Chile, Argentina, Rest of South America)
- RoW (Saudi Arabia, UAE, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product Type, Cancer Type, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global oncology informatics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
F.Hoffmann-La Roche Ltd.
Koninklijke Philips N.V.
Laboratory Corporation of America Holdings
MIM Software, Inc.
Oncology Analytics, Inc
UnitedHealth Group, Inc
Varian Medical Systems, Inc
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)